1.Clozapine-related Sudden Pericarditis in a Patient Taking Long Acting Aripiprazole and Valproate: A Case Report.
Domenico DE BERARDIS ; Michele FORNARO ; Laura ORSOLINI ; Luigi OLIVIERI ; Francesco NAPPI ; Gabriella RAPINI ; Federica VELLANTE ; Cosimo NAPOLETANO ; Nicola SERRONI ; Massimo DI GIANNANTONIO
Clinical Psychopharmacology and Neuroscience 2018;16(4):505-507
Clozapine may be associated with cardiovascular adverse effects including QTc prolongation and, more rarely, with myocarditis and pericarditis. Although rare, these latter cardiovascular adverse effects may be life-threatening and must be immediately recognized and treated. Several cases of clozapine related-pericarditis have been described and often it has a subtle and insidious onset with symptoms that may be often misdiagnosed with psychiatric manifestations (e.g. anxiety, panic or somatization) leading to a delayed correct diagnosis with potential fatal consequences. In the present report we describe the case of a 27-year-old girl with schizoaffective disorder taking long acting aripiprazole and valproate who developed a sudden onset clozapine-related pericarditis during titration phase that resolved with immediate clozapine discontinuation and indomethacin administration. We underline the importance of an early diagnosis of clozapine-related pericarditis and the need to have monitoring protocols to prevent this potentially fatal adverse effect especially when polypharmacy is administered to patients taking clozapine.
Adult
;
Anxiety
;
Aripiprazole*
;
Clozapine
;
Diagnosis
;
Drug Monitoring
;
Early Diagnosis
;
Female
;
Humans
;
Indomethacin
;
Myocarditis
;
Panic
;
Pericarditis*
;
Polypharmacy
;
Psychotic Disorders
;
Valproic Acid*
2.‘Z-trip’? A Comprehensive Overview and a Case-series of Zolpidem Misuse
Laura ORSOLINI ; Stefania CHIAPPINI ; Paolo GRANDINETTI ; Angelo BRUSCHI ; Roberta TESTA ; Alessandra PROVENZANO ; Domenico De BERARDIS ; Umberto VOLPE
Clinical Psychopharmacology and Neuroscience 2021;19(2):367-387
Although believed safer compared to short-acting benzodiazepines (BZD), in the past few years a growing concern has developed relating to the abuse of Z-drugs, and specifically of zolpidem. Here we aim to review the evidence for the misuse of zolpidem and describe several related cases collected in Italy. A comprehensive overview is here carried by using several databases, and by combining the search strategy of free text terms and exploding a range of MESH headings relating to the topics of Zolpidem and Abuse and/or Misuse as follows: ((Zolpidem [Title/Abstract]) AND (Abuse [Title/Abstract]) OR (Misuse [Title/Abstract])), without time and/or language restrictions. Furthermore, a case series of 8 cases of zolpidem misuse and/or abuse, collected in different Italian psychiatric settings (psychiatric public hospital, psychiatric private rehabilitation clinic, and private practice), have been here described. According to our findings, zolpidem should be prescribed with the same caution as BZDs, especially in patients with a history of drug abuse or in the elderly. Behavioural modifications, including bizarre behaviours, psychomotor agitation, sleep-related complex behaviours have been reported. Monitoring of zolpidem use in selected populations is warranted. Psychiatrists and physicians should be aware of the misuse potential of zolpidem and adopt measures restricting its use.
3.Trazodone Add-on in COVID-19-related Selective Serotonin Reuptake Inhibitor-resistant Post-traumatic Stress Disorder in Healthcare Workers: Two Case Reports
Domenico De BERARDIS ; Michele FORNARO ; Antonio VENTRIGLIO ; Alessandro VALCHERA ; Federica VELLANTE ; Mauro PETTORRUSO ; Giovanni MARTINOTTI ; Silvia FRATICELLI ; Massimo Di GIANNANTONIO
Clinical Psychopharmacology and Neuroscience 2021;19(4):780-785
COVID-19 represents a significant stress factor for all people worldwide due to several factors, including quarantine, lockdowns, fear of contagion, deaths, and other traumatic events. However, the healthcare workers (HCWs) have paid the higher price of this pandemic in terms of fatalities, contagions, and psychological well-being. Studies suggest that this particular population is at increased risk of developing a severe post-traumatic stress disorder (PTSD). The early diagnosis and timely treatment of PTSD in HCWs may restore well-being and significantly impact health services functioning, reducing burnout, days spent far from work, disrupted personal and team empowerment, and worse job performances. In the present article, we reported on two cases of HCWs directly involved in the treatment of COVID-19patients who showed selective serotonin reuptake inhibitor-resistant PTSD, which was successfully treated with extended-release trazodone TRZ ContramidⓇ add-on.
4.‘Z-trip’? A Comprehensive Overview and a Case-series of Zolpidem Misuse
Laura ORSOLINI ; Stefania CHIAPPINI ; Paolo GRANDINETTI ; Angelo BRUSCHI ; Roberta TESTA ; Alessandra PROVENZANO ; Domenico De BERARDIS ; Umberto VOLPE
Clinical Psychopharmacology and Neuroscience 2021;19(2):367-387
Although believed safer compared to short-acting benzodiazepines (BZD), in the past few years a growing concern has developed relating to the abuse of Z-drugs, and specifically of zolpidem. Here we aim to review the evidence for the misuse of zolpidem and describe several related cases collected in Italy. A comprehensive overview is here carried by using several databases, and by combining the search strategy of free text terms and exploding a range of MESH headings relating to the topics of Zolpidem and Abuse and/or Misuse as follows: ((Zolpidem [Title/Abstract]) AND (Abuse [Title/Abstract]) OR (Misuse [Title/Abstract])), without time and/or language restrictions. Furthermore, a case series of 8 cases of zolpidem misuse and/or abuse, collected in different Italian psychiatric settings (psychiatric public hospital, psychiatric private rehabilitation clinic, and private practice), have been here described. According to our findings, zolpidem should be prescribed with the same caution as BZDs, especially in patients with a history of drug abuse or in the elderly. Behavioural modifications, including bizarre behaviours, psychomotor agitation, sleep-related complex behaviours have been reported. Monitoring of zolpidem use in selected populations is warranted. Psychiatrists and physicians should be aware of the misuse potential of zolpidem and adopt measures restricting its use.
5.COVID-19 Impact on the Italian Community-based System of Mental Health Care: Reflections and Lessons Learned for the Future
Andrea AMERIO ; Eleonora VAI ; Edoardo BRUNO ; Alessandra COSTANZA ; Andrea ESCELSIOR ; Anna ODONE ; Domenico De BERARDIS ; Andrea AGUGLIA ; Gianluca SERAFINI ; Mario AMORE ; Seyyed Nassir GHAEMI
Clinical Psychopharmacology and Neuroscience 2023;21(1):2-9
Despite the unprecedented wave of research and publications sparked by the recent pandemic, only few studies have investigated the impact of COVID-19 on the Italian community-based system of mental health care. We aimed to summarize the available evidence from the literature also considering what we have learned from our daily clinical practice.As hospital care was restricted by COVID-19, although reducing their opening hours and activities, Community Mental Health Centers promoted continuity of care for at-risk populations, supporting them to cope with loneliness and hopelessness during quarantine and self-isolation. Ensuring continuity of care also remotely, via teleconsultation, lowered the risk of psychopathological decompensation and consequent need of hospitalization for mental health patients, with satisfaction expressed both by patients and mental health workers. Considering what we have learned from the pandemic, the organization and the activity of the Italian community-based system of mental health care would need to be implemented through 1) the promotion of a “territorial epidemiology” that makes mental health needs visible in terms of health care workers involved, 2) the increase of mental health resources in line with the other European high-income countries, 3) the formalization of structured initiatives of primary care and mental health cooperation, 4) the creation of youth mental health services following a multidimensional and multidisciplinary approach and encouraging family participation, 5) the promotion of day centers, to build competence and self-identity within a more participatory life, and programs geared to employment as valid models of recovery-oriented rehabilitation.
6.Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases
Domenico De BERARDIS ; Gabriella RAPINI ; Luigi OLIVIERI ; Agostina GIARDINI ; Ida De LAURETIS ; Nicola SERRONI ; Laura ORSOLINI ; Michele FORNARO ; Felice IASEVOLI ; Sabatino TROTTA ; Paolo COTTURA ; Federica VELLANTE ; Marco ALESSANDRINI ; Massimo Di GIANNANTONIO
Clinical Psychopharmacology and Neuroscience 2021;19(1):174-178
Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D2 /D3 receptors with preferential binding to the D 3 receptor, antagonism of 5HT2B receptors, and partial agonism of 5HT1A . Currently, cariprazine has shown clinical efficacy in patients with schizophrenia and with bipolar disorder, as well as adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD. In the present case series, we report on two patients with treatment-resistant schizophrenia and partial response to clozapine who benefit from combination with cariprazine. The effects of cariprazine combination were remarkable also concerning the adverse metabolic effects of clozapine.
7.Alexithymia, Suicide Ideation and Homocysteine Levels in Drug Naïve Patients with Major Depression: A Study in the “Real World” Clinical Practice
Domenico DE BERARDIS ; Luigi OLIVIERI ; Gabriella RAPINI ; Serena DI NATALE ; Nicola SERRONI ; Michele FORNARO ; Laura ORSOLINI ; Alessandro VALCHERA ; Alessandro CARANO ; Federica VELLANTE ; Paola Annunziata VARASANO ; Gabriella Lucidi PRESSANTI ; Gianluca SERAFINI ; Maurizio POMPILI ; Giovanni MARTINOTTI ; Massimo DI GIANNANTONIO
Clinical Psychopharmacology and Neuroscience 2019;17(2):318-322
OBJECTIVE: This study was performed to elucidate relationships between alexithymia, suicide ideation and homocysteine levels in drug-naïve outpatients with major depressive disorder (MDD). METHODS: Sixty seven outpatients with MDD with melancholic features were evaluated by the means of the Hamilton Depression Rating Scale, the Toronto Alexithymia Scale (TAS–20), the Scale of Suicide Ideation, and homocysteine levels. RESULTS: Alexithymic subjects showed higher scores on all scales and higher homocysteine levels. Regression analysis shown higher homocysteine levels and TAS-20’ “Difficulty in Describing Feelings” dimension, in turn being associated with higher suicide ideation. CONCLUSION: In conclusion, alexithymic MDD outpatients may characterize for homocysteine dysregulation that may be linked to suicide ideation, regardless depression’ severity. However, study limitations are discussed and must be considered.
Affective Symptoms
;
Depression
;
Depressive Disorder, Major
;
Homocysteine
;
Humans
;
Outpatients
;
Suicidal Ideation
;
Suicide
;
Weights and Measures
8.Understanding the Complex of Suicide in Depression: from Research to Clinics
Laura ORSOLINI ; Roberto LATINI ; Maurizio POMPILI ; Gianluca SERAFINI ; Umberto VOLPE ; Federica VELLANTE ; Michele FORNARO ; Alessandro VALCHERA ; Carmine TOMASETTI ; Silvia FRATICELLI ; Marco ALESSANDRINI ; Raffaella LA ROVERE ; Sabatino TROTTA ; Giovanni MARTINOTTI ; Massimo DI GIANNANTONIO ; Domenico DE BERARDIS
Psychiatry Investigation 2020;17(3):207-221
Objective:
Amongst psychiatric disorders, major depressive disorder (MDD) is the most prevalent, by affecting approximately 15–17% of the population and showing a high suicide risk rate equivalent to around 15%. The present comprehensive overview aims at evaluating main research studies in the field of MDD at suicide risk, by proposing as well as a schematic suicide risk stratification and useful flow-chart for planning suicide preventive and therapeutic interventions for clinicians.
Methods:
A broad and comprehensive overview has been here conducted by using PubMed/Medline, combining the search strategy of free text terms and exploded MESH headings for the topics of ‘Major Depressive Disorder’ and ‘Suicide’ as following: ((suicide [Title/Abstract]) AND (major depressive disorder [Title/Abstract])). All articles published in English through May 31, 2019 were summarized in a comprehensive way.
Results:
Despite possible pathophysiological factors which may explain the complexity of suicide in MDD, scientific evidence supposed the synergic role of genetics, exogenous and endogenous stressors (i.e., interpersonal, professional, financial, as well as psychiatric disorders), epigenetic, the hypothalamic-pituitary-adrenal stress-response system, the involvement of the monoaminergic neurotransmitter systems, particularly the serotonergic ones, the lipid profile, neuro-immunological biomarkers, the Brain-derived neurotrophic factor and other neuromodulators.
Conclusion
The present overview reported that suicide is a highly complex and multifaceted phenomenon in which a large plethora of mechanisms could be variable implicated, particularly amongst MDD subjects. Beyond these consideration, modern psychiatry needs a better interpretation of suicide risk with a more careful assessment of suicide risk stratification and planning of clinical and treatment interventions.